How to Analyse an Agrochemicals Stock (CSM, Season, RM)

In the September 2025 quarter, Rallis India earned ₹102 crore of net profit. Two quarters later, in the March 2026 quarter, the same company posted a net loss of ₹15 crore (Inve data, Q4 FY26). Nothing was broken. No fraud, no write-off, no demand collapse. It was just March instead of September — the difference between the kharif selling season at its peak and the agrochemical year at its trough. (Illustration of how to read the numbers, not a view on the stock.)

That single contrast is the first thing to internalise about this sector, and the thing most beginners get wrong: an agrochemical company's quarter tells you almost nothing until you know which quarter it is. Annualise the September print and Rallis looks like a 20%-margin compounder; annualise the March print and it looks like it's dying. Both readings are wrong, because the business doesn't run on a calendar — it runs on a monsoon.

This is how to read an agrochemicals company the way a sector analyst does: the handful of operating numbers that actually decide the outcome, where to find the ones that never appear in the income statement, and the one structural question that separates a durable contract-manufacturer from a price-taking generic. A note on the boundary first — you cannot underwrite next year's rainfall or the China technical-price cycle from a transcript. What you can do is read whether a company's earnings rest on a visible order book or on a season nobody controls.

What actually drives the economics here?

An agrochemical company makes molecules that kill the things that eat crops — insecticides, herbicides, fungicides — plus, increasingly, biologicals and plant-growth products. But "agrochemicals" is really two very different businesses wearing one label, and conflating them is the costliest mistake in the sector.

The first is the domestic branded / generic business: selling formulated product to Indian farmers through a dealer channel. It is high-margin in a good season, brutally seasonal, and exposed to two things the company cannot control — the monsoon and the price of off-patent technicals, which collapse when Chinese capacity floods the market. The second is CSM (custom synthesis / contract manufacturing): making patented molecules under long-term contract for global innovators like Bayer, Corteva or Syngenta. CSM is lower headline margin but far steadier, because it runs on multi-year order books and intellectual-property relationships, not on whether it rained in Maharashtra.

The whole craft of analysing this sector is reading the mix between those two engines — and refusing to value cyclical generic earnings as if they were contracted ones.

The metric that decides everything: CSM order book vs domestic mix

The single most important number in this sector usually isn't in the financial statements at all. It's the CSM order book — the dollar value of contracted, multi-year manufacturing work a company has already won — and you find it buried in concall Q&A and investor decks, not in the P&L.

PI Industries, the cleanest CSM example in India, carried a CSM order book of $1.25 billion as of the September 2025 quarter (PI Industries Q2 FY26 concall). That figure is the company telling you, with a straight face, that a large slice of the next several years of revenue is already booked. Compare that visibility to Rallis, whose management admitted in the same period that "I keep saying that we haven't still cracked a ₹500 crore manufacturing opportunity yet" (Rallis India Q1 FY26 concall) — i.e. its CSM ambition is still a target, not a backlog. Same sector, opposite earnings quality.

Here is the consequence that matters for valuation. When the global agrochemical cycle turned down in FY26, PI's CSM gross margin held around 50–52% (PI Industries Q4 FY25 concall: "this will remain around 50% to 52% depending on the final product mix") and its full revenue ran near ₹6,935 crore over the four quarters to December 2025 with ~₹1,450 crore of net profit (Inve data, trailing four quarters to Q3 FY26) — bumpy, but never loss-making. Rallis, far more exposed to domestic generic and seasonality, swung from ₹102 crore quarterly profit to a quarterly loss inside the same year. A visible order book is what lets one company breathe through the cycle and forces the other to hold its breath.

Think of it as the difference between a tenant on a five-year lease and one paying by the night. Both pay rent. Only one lets you sleep.

Where to find it: the order-book number is almost never tabulated — it surfaces when an analyst asks for it on the call, often guarded ("we generally keep track on the overall order book position, which is around $1.25 billion" — PI Industries Q2 FY26 concall, in response to a direct order-book question). For the domestic-CSM split, dig the investor PPT and the management's segment commentary; the income statement won't break it out for you.

Why does seasonality break naive quarter-math?

The Indian agrochemical year is built around two cropping seasons — kharif (sown June–July with the southwest monsoon, sold mostly in the July–September quarter) and rabi (winter crop, the October–March window). Kharif is by far the bigger season for most crop-protection names, which is why the September quarter is the make-or-break print and the March quarter is structurally weak.

Look at how violently this shows up. Rallis, FY26 (Inve data):

The September quarter alone carried more than half the year's profit; the March quarter lost money. So the only honest unit of analysis for an agrochemical company is the full year, or a four-quarter trailing figure — never a single quarter annualised. A company that prints a blockbuster September and a media headline that calls it a "300% jump" is not growing 300%; it is being seasonal, on cue.

The deeper use of seasonality is comparative: read this kharif against last kharif, this rabi against last rabi. Sequential (QoQ) comparison in this sector is noise; year-on-year, same-season comparison is the signal. And watch the monsoon itself — a delayed or deficient monsoon doesn't just dent volume, it strands product in the channel, which brings us to the number that ruins more agrochemical quarters than weak demand does.

Channel inventory: the number that hides a bad season

Agrochemicals are sold on credit through a dealer-distributor channel. That creates a temptation no quarterly P&L exposes: a company can "sell" to its own channel — push product onto dealers — and book revenue even if the farmer never bought it. When the season is poor, that stranded inventory sits in the channel, and the reckoning comes one or two quarters later as returns, discounts, or a quarter where the company simply can't ship because dealers are still clearing old stock.

You will rarely see "channel inventory" as a line item. You read it through three proxies. First, working-capital and receivable days — a sudden stretch means product has moved to dealers but cash hasn't come back. PI Industries flagged its trade working-capital days "increased to 139 days of sales" in the December 2025 quarter (PI Industries Q3 FY26 concall), against a normalised range nearer 65–73 days the company had guided to a year earlier (PI Industries Q4 FY25 concall) — a real, citable stretch worth a hard question. Second, volume vs value growth: if value grows while volume is flat or down, you're seeing price, not demand. Dhanuka guided to "a 2% increase in the overall volume versus value, 2% higher value because of the price increase" (Dhanuka Agritech Q1 FY26 concall) — honest disclosure of exactly that split. Third, the concall itself — a confident management volunteers channel-inventory health; an evasive one waits to be asked.

Exports, raw material, and the China question

Two external forces sit underneath every agrochemical P&L, and both lead the financials by quarters.

Exports are where the steadier money increasingly lives — global generic and CSM demand, denominated in dollars, less hostage to one country's monsoon. Sumitomo Chemical India grew export volumes "over 30% in FY25" and lifted export revenue share toward 15–17% (Sumitomo Chemical India Q4 FY25 and Q2 FY26 concalls). A rising, diversified export share is generally a quality signal; a company wholly dependent on the Indian kharif is a leveraged bet on rainfall.

Raw material is the other half. Most Indian agrochemical makers depend on Chinese intermediates and technicals, directly or through Indian importers. When China floods the market, technical prices crash — good for buyers, ruinous for anyone holding high-cost inventory. Sumitomo lost "almost 12% to 15%" of margin in one quarter purely from high-cost inventory drawing down into falling prices (Sumitomo Chemical India Q2 FY24 concall). The exposure is real and current: Dhanuka's management put direct China sourcing at "in the range of 10% to 15%" of procurement, while conceding indirect exposure through Indian importers is "difficult to say" (Dhanuka Agritech Q3 FY26 concall). That candour about the indirect number is itself worth more than the headline percentage — it tells you the true China dependence is higher than any single figure admits.

How should you value an agrochemicals stock?

The right multiple depends entirely on which engine dominates — and the market, correctly, pays up for visibility.

For a CSM-heavy name, the order book gives multi-year earnings visibility, so the market awards a higher, more stable P/E and you can sensibly value it on forward earnings. PI Industries traded around a 33.6x P/E (Screener.in) — a premium the market grants precisely because a $1.25 billion order book makes the next few years legible. For a cyclical, domestic-generic-heavy name, the danger is valuing a peak-season or peak-cycle year as if it were the run-rate. Rallis traded near a 28.4x P/E (Screener.in) — but on FY26 net profit of ₹184 crore (Inve data, four quarters to Q4 FY26) that was a depressed year, so the trailing multiple flatters a trough. For cyclicals, normalise: value on mid-cycle earnings, not the last twelve months.

The practical rule: P/E for the CSM book, normalised earnings for the generic book — and never the same multiple for both. A company that is 70% contracted CSM and one that is 70% monsoon-dependent generic should not trade on the same number, even at identical headline margins, because one set of earnings is contracted and the other is rented from the weather.

A worked case: the guidance that quietly walked down

Said-versus-did is where the sector reveals itself, and Dhanuka's FY26 Bayer-products guidance is a clean, fully-sourced example of why you track guidance across quarters rather than trusting a single call.

In May 2025, after acquiring international rights to two Bayer fungicide molecules, management guided that "revenue contribution from both products combined in this year we are looking at about Rs.110 crores, including India brand sales and international sales" (Dhanuka Agritech Q4 FY25 concall). By the September-quarter call, that had been revised down: "the number would be in the range of around INR40 crores in this financial year" (Dhanuka Agritech Q2 FY26 concall). And by the December-quarter call, lower again: "because of the grape season not behaving as per our expectation, it would not be Rs. 40 crores. It would be significantly lower than Rs. 40 Cr. Maybe around Rs. 30 crores" (Dhanuka Agritech Q3 FY26 concall). (Illustration, not a view on the stock — and a read on how guidance moved through one season, not a lifetime verdict.)

Notice what this is and isn't. It is not evidence of dishonesty — the stated reason, a poor grape season, is exactly the monsoon-and-crop dependence this whole guide is about, and management disclosed each revision plainly. It is a textbook agrochemical lesson: a forward number from this sector is a function of a season nobody controls, so an investor who annualised the ₹110 crore guide and built it into a model was modelling the weather. A guide that only ever moves one direction — down, as the season disappoints — is the pattern no single call reveals. Pinning each forward commitment to the quarter and quote it was made in, then watching what happens next, is what Inve's Promise Tracker is built to surface — the same discipline you'd bring to reading any concall transcript, sharpened for a sector that runs on rain.

Red flags specific to agrochemicals

• A single blockbuster quarter sold as a growth story. A 200–300% September jump is kharif, not a re-rating. Distrust any narrative that annualises one season.
• Value growth outrunning volume growth, quarter after quarter. Price-led growth on flat volumes can mean the channel is full and the company is pushing price to hide it.
• Working-capital and receivable days stretching with no explanation — product has moved to dealers, cash hasn't come back. PI's jump to 139 trade-working-capital days (PI Industries Q3 FY26 concall) is the kind of move that earns a question, not a pass.
• Heavy reliance on a handful of off-patent generic molecules whose price is set in China. One capacity wave there can erase a year's margin.
• CSM "order book" quoted vaguely or never updated. A real backlog gets a dollar figure on demand; a hand-wave means it's a hope.
• Margin held up by inventory gains in a falling-price environment — a one-time tailwind that reverses, exactly as Sumitomo's high-cost-inventory hit showed in reverse.

Frequently asked questions

Where this read can be wrong. The strongest case against everything above is that the order book is not a moat. A $1.25 billion CSM backlog is only as good as the innovators behind it: if a patented molecule the contract was built around fails its field trials, gets out-competed, or the innovator in-sources, the book can shrink faster than any P&L shows — and the steadiness investors paid a 33x multiple for evaporates. Equally, a "boring" seasonal generic name with a strong brand and dealer relationships can out-compound a CSM darling through a single global de-stocking cycle, as FY24–FY25 showed when global innovators cut inventory and CSM revenues stalled. So the honest claim is narrow: the mix tells you the shape of the risk — contracted vs weather-and-China — not which stock wins. It lowers your odds of valuing rented earnings as if they were owned.

Invert the question you bring to an agrochemical result. Don't ask "was this a good quarter?" — the season already answered that. Ask: if this company's earnings were entirely a function of one good monsoon and one favourable China price cycle, what would the numbers look like — and does the order book, the export mix, and the working-capital trend rule that out? A blockbuster September with stretching receivables and a vague order book does not rule it out; it is the pattern itself.

And the owner's question, to sit with before buying any agrochemical stock: across the next five years — through at least one bad monsoon and one Chinese price war — how much of this company's earnings is contracted, and how much is rented from the weather? Inve's KPI Screener lines up the operating metrics — order-book, segment mix, working-capital days, export share — across crop-protection names with a data-confidence flag per number, and the concall summaries pull every forward commitment into one guidance table per quarter. If the honest answer to the owner's question leans on rainfall rather than the order book, you've read the headline, not the business. For a contrast in how a balance-sheet business is read instead, see how to analyse an NBFC.

Related reading

• How to Analyse a Bank Stock (NIM, CASA, GNPA, ROA)
• How to Analyse a Building Products Company (Pipes, Tiles)
• How to Analyse a Cables and Wires Stock